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The aim of this study was to investigate the impact of
midgut versus hindgut as the primary tumor site in patients
with metastatic colorectal cancer (mCRC) receiving
chemotherapy with FuFIRI or mIROX. We analyzed 423
patients from a phase III trial that randomized patients in a
1 : 1 fashion to either FuFIRI or mIROX. The cohort was
grouped into midgut (n = 82) and hindgut (n = 341) primary
tumors. The primary tumor site (midgut vs. hindgut)
was correlated with parameters of treatment efficacy
and survival. Our cohort comprised 82 patients presenting
with primary midgut tumors and 341 with primary
hindgut tumors. Tumors of midgut origin compared with
hindgut origin were associated with inferior outcome.
Objective response rate was 37 versus 43% (P = 0.34),
median progression-free survival was 6.0 versus 8.2
months (P = 0.024, hazard ratio: 0.75), and median overall
survival was 13.6 versus 21.8 months (P = 0.001, hazard
ratio: 0.65). Patients with midgut mCRC showed a
clear trend toward inferior outcome in both study arms.
However, the effect appeared less pronounced in the
mIROX arm. Further datasets from large trials with various
regimens are required as confirmation. Anti-Cancer Drugs
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Introduction
In metastatic colorectal cancer (mCRC) various progno-
stic factors have been introduced to clinical practice in
recent years. In addition to clinical characteristics or
prognostic scores such as Köhne’s score [1] and similar
scores for early mortality [2], molecular markers correlat-
ing with poor outcome have been identified. Of those,
BRAF mutation, especially, has proven its prognostic
power in mCRC patients in a number of reports [3–6].
KRAS/NRAS mutation as a frequent event in mCRC can
be seen as a likely prognostic factor because of fewer
treatment options when compared with KRAS/NRAS
wild-type mCRC [3,7]. KRAS mutation is an established
negative predictive marker to guide anti-EGFR antibody
treatment such as cetuximab and panitumumab in
mCRC [4,8–12] and will be complemented by further,
rare KRAS and NRAS mutations [3].
Interestingly, many publications over recent decades have
suggested that cancers arising at different sides of the
colon (right vs. left) may represent different subtypes of
disease [13–18]. Most of these reports used the splenic
flexure as the demarcation line of proximal (right-sided,
midgut) and distal (left-sided, hindgut) colorectal
tumors. However, the resulting two-colon concept was
widely ignored by clinical trials in the following years.
Therefore, data from large randomized trials are lacking,
while data from registries provide unclear results [19,20].
In the light of more and more molecular markers and
personalized medicine being the major goal of clinical
oncology, some recent reports have again addressed the
question as to whether patients with colorectal cancer
whose primary tumor was located at the right side of the
colon have a different (worse) prognosis compared with
patients with primary tumor site in the remaining left
part of the colon when relapsing after surgery [21].
Furthermore, reports have associated the localization of
the primary tumor with the efficacy of cetuximab [21,22].
These abstracts have raised the question as to whether
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the localization of the primary tumor in colorectal cancer
can serve as prognostic and/or predictive marker. To date,
it is unclear whether the poor prognostic effect of right-
sided (midgut) colorectal cancer depends on the therapeutic
situation (adjuvant or palliative treatment) and the respec-
tive treatment line. In particular, effects may differ between
chemotherapy-naive patients and populations with che-
motherapy-refractory tumors. To our knowledge, the effect
of primary tumor localization on outcome has not been shown
in an mCRC study population receiving first-line treatment.
This exploratory analysis aims to investigate the impact of
primary tumor site (midgut vs. hindgut tumors) on
prognosis and therapeutic efficacy in patients with
mCRC receiving either FuFIRI or mIROX as first-line
treatment. This study allows the investigation of the
effect of primary tumor site in patients receiving
chemotherapy alone, without the addition of monoclonal
antibodies. Moreover, as one treatment arm is free of
oxaliplatin, while the other does not contain 5-FU, effects
evaluated in this setting may generate hypotheses




Data for this analysis were obtained from the FIRE1 trial.
This study was a randomized, multicenter phase III trial
to investigate the efficacy of FuFIRI versus mIROX as
first-line chemotherapy in patients with mCRC and
was carried out between 2000 and 2004. The study was
conducted according to the Declaration of Helsinki and
was approved by the local ethics committee. Regular site
visits were performed. Tumor assessments were per-
formed preferably by computed tomography scans, but
also by MRI, radiograph, and ultrasound. During therapy,
tumor assessments were carried out after the first and
second cycle, and thereafter every two cycles. Response
was evaluated by the WHO criteria. The study was
funded by Aventis and Pfizer [23].
Assessment of primary tumor site
The FIRE1 trial recorded primary tumor site by rectum
versus colon tumors. The present evaluation was
performed based on retrospective assessment of primary
tumor site that was conducted according to guidelines
provided by the ethics committee of the University of
Munich (No. 545-11). All data were acquired and
analyzed anonymously.
Definition of midgut versus hindgut tumors
In the present analysis, all tumors located in the rectum,
sigma, descending colon, and left flexure were defined as
hindgut tumors (= left colon). All tumors from the cecum
to the distal part of the transverse colon were defined as
midgut tumors (= right colon).
Treatment schedule
FuFIRI: irinotecan 80 mg/m2 as a 0.5-h infusion followed by
folinic acid 500 mg/m2 applied over 2 h and 5 fluorouracil
2000 mg/m2 administered as a 24-h infusion. mIROX-
regimen (mIROX): irinotecan 80 mg/m2 as a 0.5-h infusion
six times weekly plus oxaliplatin 85 mg/m2 as 2-h infusion
on days 15 and 29 of each cycle. In both arms, treatment
was repeated every 49 days. In the case of isolated
resectable liver metastases, resection was recommended
after completion of two treatment cycles. Patients achiev-
ing complete remission (CR) received one further cycle of
therapy, and treatment was stopped only after confirmation
of CR. Patients achieving partial remission or stable disease
continued therapy until progression or toxicity. At the time
of disease progression or treatment intolerability, cross-over
from FuFIRI to mIROX and vice versa was recommended
and subsequently performed in about 69% of the study
population [23].
Patients
Patients aged 18–75 years with histologically proven
metastatic adenocarcinoma of the colon or rectum
without prior chemotherapy for metastatic disease were
eligible. Prior adjuvant chemotherapy was allowed with a
treatment-free interval of 6 months and did not include
topoisomerase I inhibitors or platinum compounds [23].
End points
The present investigation was performed as an explora-
tory analysis using response rates (complete remission =
CR; partial remission = PR; stable disease = SD; progres-
sive disease = PD), progression-free survival (PFS), and
overall survival (OS) as reference for outcome in patients
with tumors of midgut vs. hindgut origin. PFS was
regarded as the interval between randomization and first
documentation of progression or death; OS was calculated
as the time between randomization and death because of
any reason. Patients who were alive were censored at the
last time point of patient contact. A final update on OS
was conducted in 2012.
Statistical analysis
OS and PFS stratified by primary tumor site were
estimated using the Kaplan–Meier method, and differ-
ences were evaluated by log-rank test and Cox regression
model. Response rates were compared by w2-tests. A
P-value less than 0.05 (two-sided tests) was regarded
as significant. A backward elimination from a set of
candidate predictors was performed at a significance level
of 0.05. Simultaneously to this backward elimination,
possible nonlinear relationships between a continuous
covariate and the log hazard were evaluated by fractional
polynomials. In addition, graphically based residual analyses
were performed to evaluate the assumption of proportional
hazards in the Cox regression model. SPSS PASW 21.0
(SPSS Inc., Chicago, Illinois, USA) and R, version 2.13.0
(the R Foundation for Statistical Computing/R Development
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Core Team, GNU General Public License) software were
used for statistical analysis.
Results
Study population
The exact localization of the primary tumor was
assessable in 423 patients representing 88.3% of the
whole study population. The primary tumor site could
not be assessed in 56 patients. Of these 423 patients, 82
had primary midgut tumors, whereas 341 presented
hindgut tumors. In detail, tumors were located in the
rectum (n = 189), sigma (n = 121), descending colon
(n = 22), left flexure (n = 9), transverse colon (n = 15),
right flexure (n = 12), ascending colon (n = 25), and
cecum (n = 30).
Baseline characteristics
In patients with midgut mCRC compared with the
hindgut group, a trend towards more female patients was
observed (37 vs. 28%). Moreover, performance status,
assessed by Karnofsky performance status, might have
been less favorable in the midgut cohort as compared
with the hindgut group. Comparable frequencies of
metastases, prior adjuvant treatment, and treatment arms
were observed in midgut and hindgut tumors. The
median age was 64 years in both cohorts (Table 1).
Consistency with whole study population
In the current cohort response rates reached 43% in
patients treated with FuFIRI and 40% in patients
receiving mIROX. These rates are comparable to 41%
in the whole study population that was observed in both
treatment arms. Median PFS was 8.2 months (FuFIRI)
versus 7.2 months (mIROX), respectively, in the
presented subpopulation and 8.2 and 7.2 months in
the whole study population. Median OS – following the
final update – in the present cohort was 21.8 months
(FuFIRI) versus 18.9 months (mIROX). Survival in the
full study population reached 21.0 versus 18.7 months in
the respective treatment arms.
Effect of primary tumor site on response
Objective response rate (CR, PR) was 37% in midgut
tumors, compared with 43% in hindgut tumors across
both study arms (P = 0.34). This difference was pro-
nounced in the FuFIRI arm (33 vs. 46%, P = 0.03) but
not present in the mIROX arm (40 vs. 40%, P = 0.94)
(Table 2).
Effect of primary tumor site on progression-free survival
Median PFS was 6.0 months in patients with midgut and
8.2 months in patients with hindgut tumors [P = 0.024,
hazard ratio (HR): 0.75]. Taking treatment arms into
account, 6.0 versus 8.7 months (P = 0.02, HR: 0.66) was
observed in the FuFIRI arm in midgut versus hindgut
tumors, whereas 6.0 versus 7.8 months (P = 0.35, HR:
0.84) was reached in the mIROX arm, respectively
(Fig. 1a–c).
Effect of primary tumor site on overall survival
Median OS was 13.6 months in patients with midgut
tumors and 21.8 months in patients with tumors of
hindgut origin (P = 0.001, HR: 0.65). Specifically, 12.5
versus 25.0 months (P = 0.001, HR: 0.55) was observed in
the FuFIRI arm, whereas 14.0 versus 20.4 months
(P = 0.12, HR: 0.74) was reached in the mIROX arm in
midgut versus hindgut mCRC (Fig. 2a–c).
Effect of treatment arm on outcome in midgut versus
hindgut tumors
The outcome of patients with mCRC of midgut origin was
similar in both treatment arms (FuFIRI vs. mIROX)
concerning response rates (33 vs. 40%, P = 0.7), PFS [6.0
vs. 6.0 months, P = 0.79; HR: 0.94 (0.60–1.489)] and OS
[12.5 vs. 14.5 months, P = 0.65; HR: 0.90 (0.57–1.43)]. In
patients with hindgut mCRC a slight trend toward better
outcome in the FuFIRI arm was observed. Response rates
were 46 versus 40% (P = 0.04), PFS was 8.7 versus 7.8
months [P = 0.17; HR: 1.17 (0.94–1.46)], and OS was
25.0 versus 20.4 months [P = 0.19; HR: 1.17 (0.93–1.47)].
Backward elimination algorithm for other factors
impacting outcome
The effect of midgut versus hindgut tumor site was
adjusted for several potential predictors (performance
status, age, sex, adjuvant chemotherapy, number
of metastases, liver metastasis, liver-only metastasis, lung
metastasis, lymph node metastasis, pelvic tumor lesions,
Table 1 Patient characteristics
Hindgut tumors [n (%)] Midgut tumors [n (%)]





Female 97 (28) 30 (37)
Male 244 (72) 52 (63)
Performance status (Karnofsky)
100 144 (42) 25 (30)
90 94 (27) 23 (28)
80 76 (22) 18 (22)
70 25 (7) 15 (18)
60 0 (0) 1 (1)
Not reported 2 (1) 0 (0)
Prior therapy
Chemotherapy 100 (29) 25 (30)
Tumor characteristics
Liver 290 (86) 68 (85)
Liver only metastasis 177 (52) 44 (55)
Lung 99 (29) 18 (23)
Lymph node 49 (14) 13 (16)
Peritoneum 7 (2) 2 (3)
Not reported 2 2
Treatment arm
FuFIRI 172 (50) 42 (51)
mIROX 169 (50) 40 (49)
Characteristics of patients, percentages based on nonmissing data.
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and peritoneal metastasis), by using the backward
elimination algorithm. No predictor was selected when
PFS and OS were stratified by midgut versus hindgut
tumor site. Thus, the final model consisted of the
predictor midgut versus hindgut tumor site.
Discussion
This investigation concerning the impact of primary
tumor site in mCRC on the outcome of patients was
motivated by recent reports concerning differences
between tumors of the right versus left colon.
A general issue by addressing differences between right
and left colon tumors occurs in terms of the definition of
right versus left colon that differs between the respective
cohorts and abstracts [21,22,24]. We grouped tumors into
right versus left tumors by modified midgut versus
hindgut definition. Our modification concerns the distal
third of the colon transversum, which we counted as
‘right colon’. A more precise separation of midgut versus
hindgut localization in tumors of the colon transversum
could not be deducted based on pathology reports. In our
cohort, a small number of patients presented with
primary tumors of the transverse colon (15 patients,
accounting for 3.5% of all patients). From our perspective,
a bias of potentially ‘left-colon’ tumors with regard to the
negative prognostic effect of midgut tumors seemed
unlikely. In addition, further heterogeneity between the
recently published abstracts is caused by the role of the
rectum within the definition of right versus left colon
tumors. Whereas some authors differentiate right colon
versus left colon versus rectum tumors [24], we analyzed
midgut versus hindgut tumors. Rectum tumors were not
evaluated separately. Furthermore, the strict dichotomous
separation of left versus right/midgut versus hindgut may
undergo critical re-evaluation in the light of reports that
suggest a ‘continuum hypothesis’ [18,25].
In our study cohort, objective response rate did not
indicate great differences when midgut and hindgut
tumors were compared. By contrast, PFS and OS were
markedly shorter in patients with midgut tumors when
compared with hindgut tumors. An overall survival of
about 14 months in patients with midgut mCRC is well
comparable to survival data of patients with established
factors of poor prognosis such as BRAF mutation [3,4,6,7].
Although recent reports suggest that BRAF mutation might
be present at a higher frequency in midgut versus hindgut
CRC, this may explain the great effect on OS only to a
certain extent [21]. The inferior outcome of patients with
right-sided CRC as compared with left-sided CRC was also
observed in the PETACC3 trial (adjuvant treatment) with
no difference in relapse-free survival, but a significant
difference in survival after relapse (HR: 1.97, P < 0.001)
[21]. By contrast, in chemorefractory patients with mCRC
receiving best supportive care (BSC) the tumor site did not
impact PFS or OS. Taking these observations together, it
might be suspected that the primary tumor site (right vs.
left or midgut vs. hindgut) is not a prognostic marker in
general but is associated with treatment sensitivity in
patients with metastatic/recurrent disease receiving active
treatment. However, more datasets of trials in adjuvant and
metastatic settings need to be analyzed before conclusions
concerning the prognostic power of tumor site in colorectal
cancer can be drawn.
In addition, a second effect was demonstrated in patients
with mCRC receiving cetuximab therapy: patients with
left-sided mCRC had a significantly longer PFS compared
with patients presenting with right-sided mCRC. There-
fore, Missiaglia et al. [21] concluded that left-sided
mCRC might also have a predictive value for cetuximab
therapy. This hypothesis is supported by an analysis of
the NCIC CTG CO.17 trial that investigated cetuximab
plus BSC versus BSC alone in chemorefractory patients
with mCRC. In patients receiving cetuximab therapy
longer PFS and OS in favor of patients with left-sided
compared with right-sided tumors were observed. Ac-
cordingly, when tumor sites were analyzed separately, a
clear treatment effect of cetuximab was described in
patients with KRAS wild type, left-sided tumors, whereas
less striking treatment effects were demonstrated in
KRAS wild type, right-sided tumors [22]. As the FIRE1-
trial did not contain treatment with an anti-EGFR
antibody, no conclusions can be made here. It remains an
interesting question as to whether tumor site correlates
with treatment benefit in general, with certain chemother-
apeutic regimens, and with anti-EGFR antibody use alone
or in combination with chemotherapy.
The prognostic or predictive effect of the primary tumor
localization in CRC is suspected to be at least partly
Table 2 Response to treatment
Parameters Hindgut (all patients) Midgut (all patients) Hindgut FuFIRI Midgut FuFIRI Hindgut mIROX Midgut mIROX
Number of patients 341 82 172 42 169 40
CR [n (%)] 23 (7) 9 (11) 13 (8) 3 (7) 10 (6) 6 (15)
PR [n (%)] 123 (36) 21 (26) 66 (38) 11 (26) 57 (34) 10 (25)
SD [n (%)] 119 (35) 23 (28) 69 (40) 13 (31) 50 (30) 10 (25)
PD [n (%)] 33 (10) 14 (17) 10 (6) 6 (14) 23 (14) 8 (20)
Not assessable [n (%)] 43 (13) 15 (18) 14 (8) 9 (21) 29 (17) 6 (15)
ORR (%) 43 37 46 33 40 40
CR, complete remission; Not assessable, not assessable because of any reason; ORR (CR + PR), overall response rate; PD, progressive disease; PR, partial remission;
SD, stable disease.
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influenced by the distinct occurrence of mutations and
expressions of key markers including BRAF, KRAS,
PI3KCA, MSI, EREG, EGFR, HER2, ERCC1, TS2, and
VEGFR2 [13,16]. Specifically, a recent report suggested
that ERCC1 and TS2 expression appears to be KRAS and
primary tumor-site dependent [24]. Taking this into
account, interaction of tumor side and treatment arm
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Progression-free survival according to localization of the primary
tumor. (a) All patients; (b) patients receiving FuFIRI as first-line
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Overall survival according to localization of the primary tumor. (a) All
patients; (b) patients receiving FuFIRI as first-line treatment; (c) patients
receiving mIROX as first-line treatment. HR, hazard ratio.
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the survival of patients with midgut versus hindgut
mCRC did not show a significant interaction with the
respective treatment or with other subgroups in our
population as shown in the backward elimination algorithm.
Nevertheless, although not significant, the prognostic
effect of primary tumor site appeared more pronounced
in the FuFIRI arm compared with the mIROX arm.
Hindgut tumors were associated with a slight trend
toward better outcome in the FuFIRI arm compared with
the mIROX arm, which is in accordance with the whole
study population. By contrast, in patients with midgut
tumors response rates were rather favorable in the
mIROX arm, whereas PFS and OS were comparable in
both arms. These hypothesis-generating trends in small
subsets stress the need for further analysis of different
therapeutic settings and various regimens.
Our results are limited by the number of patients included
and in some ways by the absence of antibodies in first-line
treatment as well as in second-line treatment [23]. This
trial finished in 2004, and thus only a minority of patients
might have been exposed to cetuximab or bevacizumab in
later treatment lines; these data are not available. Never-
theless, the significant impact of midgut versus hindgut
tumor on outcome of patients in a cohort treated without
antibodies for at least two treatment lines in a clear
majority of patients is an interesting finding.
Conclusion
On the basis of our findings and the limited data that
have been published thus far, suspicion arises that
compared with midgut tumors, hindgut tumors are
associated with less favorable treatment effects in
metastatic/recurrent CRC. In addition, this effect might
partly depend on the treatment given. Further datasets
from large trials with and without anti-EGFR antibodies
are required before more conclusions can be drawn.
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4 Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S,
et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line
treatment for metastatic colorectal cancer: updated analysis of overall
survival according to tumor KRAS and BRAF mutation status. J Clin Oncol
2011; 29:2011–2019.
5 Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF
mutation is a powerful prognostic factor in advanced and recurrent
colorectal cancer. Br J Cancer 2011; 104:856–862.
6 Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C,
et al. The influence of KRAS and BRAF mutations on the efficacy
of cetuximab-based first-line therapy of metastatic colorectal cancer:
an analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131:
980–986.
7 Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH,
et al. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-
based first-line combination chemotherapy for treatment of advanced
colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Lancet 2011; 377:2103–2114.
8 Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J,
de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin
Oncol 2009; 27:663–671.
9 Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al.
Randomized, phase III trial of panitumumab with infusional fluorouracil,
leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line
treatment in patients with previously untreated metastatic colorectal cancer:
the PRIME study. J Clin Oncol 2010; 28:4697–4705.
10 Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al.
Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;
357:2040–2048.
11 Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D,
Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced
colorectal cancer. N Engl J Med 2008; 359:1757–1765.
12 Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al.
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol 2008; 26:
1626–1634.
13 Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002;
101:403–408.
14 Carethers JM. One colon lumen but two organs. Gastroenterology 2011;
141:411–412.
15 Bufill JA. Colorectal cancer: evidence for distinct genetic categories
based on proximal or distal tumor location. Ann Intern Med 1990; 113:
779–788.
16 Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and
clinical implications. J Surg Oncol 2004; 88:261–266.
17 Albuquerque C, Bakker ER, van Veelen W, Smits R. Colorectal
cancers choosing sides. Biochim Biophys Acta 2011; 1816:
219–231.
18 Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT,
Giovannucci E, et al. Colorectal cancer: a tale of two sides or a continuum?
Gut 2012; 61:794–797.
19 Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H.
Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison
of 17,641 patients with right- and left-sided colon cancer: differences in
epidemiology, perioperative course, histology, and survival. Dis Colon
Rectum 2010; 53:57–64.
20 Weiss JM, Pfau PR, O’Connor ES, King J, LoConte N, Kennedy G,
Smith MA. Mortality by stage for right- versus left-sided colon cancer:
analysis of surveillance, epidemiology, and end results – Medicare data.
J Clin Oncol 2011; 29:4401–4409.
Analysis of the FIRE1-trial Modest et al. 217
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
21 Missiaglia E, Jacobs B, Di Narzo AF, Soneson C, Roth A, Bosman F, et al.
Proximal and distal colon tumors as distinct biologic entities with different
prognoses [abstract]. J Clin Oncol 2013; 31 (Suppl):3526.
22 Brule SY, Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R,
et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a
predictor of benefit from cetuximab (CET): NCIC CTG CO.17 [abstract].
J Clin Oncol 2013; 31 (Suppl):3528.
23 Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach
PA, Lambertz H, et al. Phase III trial of irinotecan plus infusional
5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line
treatment of advanced colorectal cancer. Eur J Cancer 2011; 47:206–214.
24 Maus MKH, Hanna DL, Stephens C, Grimminger PP, Epstein M, Astrow SH,
et al. Gene expression profiles and tumor locations in colorectal cancer (left
vs. right vs. rectum) [abstract]. J Clin Oncol 2013; 31 (Suppl):3527.
25 Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al.
Assessment of colorectal cancer molecular features along bowel subsites
challenges the conception of distinct dichotomy of proximal versus distal
colorectum. Gut 2012; 61:847–854.
218 Anti-Cancer Drugs 2014, Vol 25 No 2
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
